euro-cardiology-2017-posters-accepted-abstracts

Page 99

Notes:

conferenceseries

.com

Volume 8, Issue 9 (Suppl)

J Clin Exp Cardiolog, an open access journal

ISSN: 2155-9880

Euro Cardiology 2017

October 16-18, 2017

October 16-18, 2017 | Budapest, Hungary

European

Cardiology

Conference

J Clin Exp Cardiolog 2017, 8:9(Suppl)

DOI: 10.4172/2155-9880-C1-078

Cryoablation of atrial fibrillation and antiarrhythmic drug pretreatment: A single referral center

experience

Michael Spartalis

, Eleni Tzatzaki

, Eleftherios Spartalis

, Demetrios Moris

, Ilias Doulamis

, Andreas S Triantafyllis

, Efthimios Livanis

and

George

Theodorakis

Onassis Cardiac Surgery Center, Greece

University of Athens, Greece

The Ohio State University Comprehensive Cancer Center, USA

University Hospitals Leuven, Belgium

Background:

Pulmonary vein isolation (PVI) ablation has emerged as the gold standard of ablative strategies to treat medically

refractory paroxysmal and persistent atrial fibrillation (AF). Regardless of the superiority of catheter ablation based on PVI

over antiarrhythmic drug therapy, recurrence rates of AF remain higher than desired. Our objective was to assess the safety and

efficacy of cryoablation in a single referral center.

Methods:

This is a retrospective analysis of results after cryoablation treatment of AF over three years. 146 patients with AF

underwent a cryoablation procedure in our clinical center and were followed-up for three years after the procedure.

Results:

Cryoablation was clinically successful in 90.83% of the patients with paroxysmal AF and 60% of those with persistent

AF. The clinical success of cryoablation was correlated with pretreatment with amiodarone and in the case of re-ablation. With

respect to postoperative complications, major bleeding was correlated with female gender, treatment with rivaroxaban and

amiodarone.

Conclusion:

Freedom from recurrent AF is about 65% with follow-up limited to 1 to 2 years in major trials. We present a

durable event free result in most patients out to 3 years with better outcomes than previously reported.